Iron Fact Sheet
Database: Material Density for Common Substances
| Record Name | Material Type | Material | Density (g/cc) |
| Mineral Iron Ore | Mineral | Iron | re |
| Mineral Iron Ore | Mineral | Iron | re |
| Metal Iron | Metal | Iron | ron |
| Metal Iron | Metal | Iron | ron |
| Metal Iron | Metal | Iron | ron |
| Metal Pig Iron 7.207 | Metal | Pig Iron | .207 |
| Metal Iron | Metal | Iron | ron |
| Metal Iron | Metal | Iron | ron |
| Metal Wrought Iron 7.75 | Metal | Wrought Iron | .75 |
| Metal Pure Iron 7.86 | Metal | Pure Iron | .86 |
Database: Food Additives and their purpose
| Record Name | Primary Purpose | Code | Additive |
| 172 Iron oxide | Color | 172 | Iron oxide |
Database: Year and Discoverer of Chemical Elements
| Record Name | Element | Year Discovered | Discovered By | Source |
| Iron | Iron | Unknown | Ancient | Jefferson Lab |
Database: Pulitzer Prize Winning Novels By Year
| Record Name | Year | Title | Author |
| Ironweed, William Kennedy | 1984 | Ironweed | William Kennedy |
Database: Council of Europe's treaties
| Record Name | Treaty | European Non-Member State | Non European Non-Member State | European Community | Number | Opening date | Entry into force date | Source |
| Convention on Civil Liability for Damage resulting from Activities Dangerous to the Environment (150) | Convention on Civil Liability for Damage resulting from Activities Dangerous to the Environment | Yes | Yes | Yes | 150 | 21/6/1993 | Council of Europe | |
| Convention on the Protection of Environment through Criminal Law (172) | Convention on the Protection of Environment through Criminal Law | Yes | Yes | 172 | 4/11/1998 | Council of Europe |
Database: Average Energy Use of Common Appliances
| Record Name | Appliance | Energy (Wattage per Hour) |
| Average energy use for Iron | Iron | 1,088 |
Database: Listing of FDA Approved Oncology Drugs
| Record Name | Manufacturer/Distributor | Drug | Trade Name | Approved Use | Approval Date | Source |
| Prokine (Chiron) | Chiron | aldesleukin | Prokine | Treatment of adults with metastatic melanoma | Jan 09 1998 | U.S. Food and Drug Administration : Center for Drug Evaluation and Research |
| Proleukin (Chiron Corp) | Chiron Corp | Aldesleukin | Proleukin | Treatment of adults with metastatic renal cell carcinoma | May 05 1992 | U.S. Food and Drug Administration : Center for Drug Evaluation and Research |
| Epogen/Procrit (Amgen) | Amgen | epoetin alfa | Epogen/Procrit | is indicated for the treatment of anemia related to therapy with zidovudine in HIV-infected patients. EPOGEN® is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or hemoglobin determinations) and to decrease the need for transfusions in these patients. EPOGEN® is not indicated for the treatment of anemia in HIV-infected patients due to other factors such as iron or folate deficiencies, hemolysis, or gastrointestinal bleeding, which should be managed appropriately. | Mar 09 2007 | U.S. Food and Drug Administration : Center for Drug Evaluation and Research |
| epogen (Amgen, Inc) | Amgen, Inc | Epoetin alfa | epogen | EPOGENB is indicated for the treatment of anemia in patients with non-myeloid malignancieswhere anemia is due to the effect of concomitantly administered chemotherapy. EPOGEND is indicated to decrease the need for transfusions in patients who will be receiving concomitant chemotherapy for a minimum of 2 months. EPOGENB is not indicated for the treatment of anemia in cancer patients due to other factors such as iron or folate deficiencies, hemolysis orgastrointestinal bleeding, which should be managed appropriately. | Jul 26 1999 | U.S. Food and Drug Administration : Center for Drug Evaluation and Research |
| epogen (Amgen, Inc) | Amgen, Inc | Epoetin alfa | epogen | EPOGENB is indicated for the reatment of anemia related to therapy with zidovudine in HIV- infected patients. EPOGENB is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or hemoglobin determinations) and to decrease the need for transfusions in these patients. EPOGEND is not indicated for the treatment of anemia in HIV-infected patients due to other factors such as iron or folate deficiencies, hemolysis or gastrointestinal bleeding, which should be managed appropriately. | Jul 26 1999 | U.S. Food and Drug Administration : Center for Drug Evaluation and Research |
Database: Top Supercomputers of the world
| Record Name | Year | Country | Manufacturer | Source | Site | Processors | Rmax (GFlops) | Rpeak (GFlops) |
| eServer pSeries p5 575 1.9 GHz | 2006 | United States | IBM | Top 500 Supercomputer Sites (June 2007) | National Centers for Environmental Prediction | 2368 | 15470 | 17996.8 |
| eServer pSeries p5 575 1.9 GHz | 2006 | United States | IBM | Top 500 Supercomputer Sites (June 2007) | National Centers for Environmental Prediction | 2368 | 15470 | 17996.8 |
Database: List of Secret Societies at Universities
| Record Name | Year Established | University | Member Limit | Active or Honorary | Name | Source |
| Iron Arrow Honor Society (University of Miami) | 1926 | University of Miami | Senior | Honorary | Iron Arrow Honor Society | Wikipedia |
| Iron Cross (Secret Society) (University of Wisconsin-Madison) | 1902 | University of Wisconsin-Madison | Junior Senior | Honor | Iron Cross (Secret Society) | Wikipedia |
Database: Controlled Substances
| Record Name | Schedule | Narcotic | DEA Number | Other Names | Source |
| Mesterolone (1alpha-methyl-17beta-hydroxy-5alpha-androstan-3-one) | III | No | 4000 | Androviron, Proviron, Testiwop | United States Drug Enforcement Agency |
Database: Comic Book Super Heros by Publisher
| Record Name | Publisher | Name |
| Iron Fist | Marvel | Iron Fist |
--- END OF FACT SHEET ---